Liver Disease Stocks
Biopharmaceutical innovators in this space target high-prevalence metabolic and fibrotic conditions, specifically Non-Alcoholic Steatohepatitis (NASH) and primary biliary cholangitis, where significant unmet medical needs drive massive market potential.
As of Oct 23, 2026, Liver Disease has 19 US-listed companies worth $217B combined. The median member moved +0.4% over the past week; IVA led at +26.2% and GALT trailed at -11.9%.
Companies in Liver Disease
- GILD – Gilead Sciences Inc, $193B
- MDGL – Madrigal Pharmaceuticals Inc, $10B
- MIRM – Mirum Pharmaceuticals Inc, $5.3B
- VKTX – Viking Therapeutics Inc, $3.3B
- DMRA – Damora Therapeutics, Inc., $1.2B
- IVA – Inventiva Sa, $770M
- SGMT – Sagimet Biosciences Inc. Series A Common Stock, $633M
- ALT – Altimmune Inc, $595M
- DCTH – Delcath Systems Inc, $534M
- AVIR – Atea Pharmaceuticals Inc, $413M
- GALT – Galectin Therapeutics Inc, $374M
- TLSI – TriSalus Life Sciences Inc., $250M
- CNTN – Canton Strategic Holdings, Inc., $149M
- TARA – Protara Therapeutics Inc, $137M
- ALGS – Aligos Therapeutics Inc, $33.3M
- BIVI – Biovie Inc, $11.9M
- CANF – Can Fite Biopharma Ltd ADR, $5.9M
- GLMD – Galmed Pharmaceuticals Ltd, $4.9M
- EOCN – Eocene Ltd., $3.8M